Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: lexi2004 who wrote (57666)	2/23/2007 3:50:56 PM
From: Willsgarden	Read Replies (1) \| Respond to of 59879

up .20 hod UPBS, i'm sure it will surge on mondays open, can't pull the trigger on NEOL, maybe monday for me. bill

To: lexi2004 who wrote (57666)	2/25/2007 5:08:28 PM
From: Findit	Read Replies (1) \| Respond to of 59879

DORB - From today's Miami Herald - CEO Schaber remained upbeat. He said Cell Therapeutics is not alone in bidding on DOR and plans to listen to all offers. ``There's other interest out there, and we need to maximize shareholder value.'' In a presentation for industrial conferences, DOR estimates orBec could have a $200 million annual market worldwide and, because it is serving a severe, unmet need, the FDA is likely to declare it an orphan drug, extending its exclusivity. The firm says that it can continue to develop and market orBec on its own -- assuming it gets approval. ''This is a very interesting time,'' says Schaber. ``There's always a risk.''